Author:
Tekantapeh Sepideh Tahsini,Nader Nader D.,Ghojazadeh Morteza,Fereidouni Fatemeh,Soleimanpour Hassan
Abstract
Abstract
Background
Prone positioning (PP) is a low-cost method with minimal risk to the patient that improves the oxygenation of patients with acute hypoxic respiratory failure (AHRF) due to COVID-19 pneumonia, thereby reducing their need for tracheal intubation (TI) and transferring to the intensive care unit (ICU). We aimed to overview the results of all previous systematic reviews and meta-analyses to examine the net effect of PP on oxygenation, the rate of TI and mortality in COVID-19 patients.
Methods
We searched PubMed, Scopus, Web of Science, Google Scholar, and Cochrane Library databases from December 2019 through 2022 without publication language restriction for systematic reviews and meta-analysis studies on PP vs. supine position (SP) in conscious patients with hypoxic respiratory failure COVID-19. After study selection, data were extracted from published meta-analyses and pooled by comprehensive meta-analysis (CMA) software version 2.2.064 to achieve effect sizes. They were analyzed for TI and mortality rates dichotomous variables, and the results were shown as pooled odds ratios (OR) with a 95% confidence interval (CI). Continuous variables such as oxygenation indices (PaO2/FiO2 and SpO2) were also analyzed, and the data were shown as mean differences (MD) with lower and upper CI. The level of statistical significance was set at p ≤ 0.05.
Results
Twelve systematic reviews and meta-analyses with 19,651 patients and six systematic reviews with 2,911 patients were included in this Review of Reviews (total: 22,562). PP treatment significantly reduced the rate of TI (OR = 0.639, %95 CI (0.492, 0.829); P-value = 0.001) and decreased mortality (OR = 0.363, %95 CI (0.240, 0.549), P-value < 0.001). There was no difference in PaO2/FiO2 (MD = 3.591[− 40.881, 48.062]; P-value = 0.874) and SpO2 percent (MD = 1.641[− 4.441, 7.723]; P-value = 0.597).
Conclusion
Prone positioning can be recommended in conscious ICU patients with COVID-19 pneumonia to reduce mortality and intubation.
Systematic review registration: PROSPERO registration number: CRD42022326951. Registered 25 April 2022.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Shahsavarinia K, Ghojazadeh M, Ghabousian A, Hatefnia F, Soleimanpour M, Soleimanpour H. An umbrella review of clinical efficacy and adverse cardiac events associated with hydroxychloroquine or chloroquine with or without azithromycin in patients with COVID-19. Anesth Pain Med. 2021;11(4): e115827.
2. Shadvar K, Tagizadiyeh A, Gamari AA, Soleimanpour H, Mahmoodpoor A. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood Purif. 2021;50(3):405–7.
3. Shahsavarinia K, Ghojazadeh M, Sanaie S, Vahedi L, Ahmadpour M, Mahmoodpoor A, et al. Clinical efficacy of hydroxychloroquine or chloroquine in patients with COVID-19: an umbrella review. Pharm Sci. 2021;27(4):481–8.
4. Bagi HM, Soleimanpour M, Abdollahi F, Soleimanpour H. Evaluation of clinical outcomes of patients with mild symptoms of coronavirus disease 2019 (COVID-19) discharged from the emergency department. PLoS ONE. 2021;16(10): e0258697.
5. Mahmoodpoor A, Shadvar K, Ghamari AA, Mohammadzadeh Lameh M, Asghari Ardebili R, Hamidi M, et al. Management of critically ill patients with COVID-19: what we learned and what we do. Anesth Pain Med. 2020;10(3): e104900.